Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCGI13104

Title

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

Principal Investigator(s)

Emily Chan

Details

  • Protocol No. VICCGI13104
  • Open Date: 08/06/2014
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the investigator objective response rate (ORR) of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with metastatic MSI-H CRC.
  • Disease Sites: Colon
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Ipilimumab; Nivolumab (BMS-936558)
  • Participating Institutions: Vanderbilt University
  • Secondary Protocol No: CA209142

Description

None Provided.

Eligibility

Not provided. Please call for more information.